Synchrotron microbeam radiation therapy for rat brain tumor palliation-influence of the microbeam width at constant valley dose.

To analyze the effects of the microbeam width (25, 50 and 75 microm) on the survival of 9L gliosarcoma tumor-bearing rats and on toxicity in normal tissues in normal rats after microbeam radiation therapy (MRT), 9L gliosarcomas implanted in rat brains, as well as in normal rat brains, were irradiated in the MRT mode. Three configurations (MRT25, MRT50, MRT75), each using two orthogonally intersecting arrays of either 25, 50 or 75 microm wide microbeams, all spaced 211 microm on center, were tested. For each configuration, peak entrance doses of 860, 480 and 320 Gy, respectively, were calculated to produce an identical valley dose of 18 Gy per individual array at the center of the tumor. Two, 7 and 14 days after radiation treatment, 42 rats were killed to evaluate histopathologically the extent of tumor necrosis, and the presence of proliferating tumors cells and tumor vessels. The median survival times of the normal rats were 4.5, 68 and 48 days for MRT25, 50 and 75, respectively. The combination of the highest entrance doses (860 Gy per array) with 25 microm wide beams (MRT25) resulted in a cumulative valley dose of 36 Gy and was excessively toxic, as it led to early death of all normal rats and of approximately 50% of tumor-bearing rats. The short survival times, particularly of rats in the MRT25 group, restricted adequate observance of the therapeutic effect of the method on tumor-bearing rats. However, microbeams of 50 microm width led to the best median survival time after 9L gliosarcoma MRT treatment and appeared as the better compromise between tumor control and normal brain toxicity compared with 75 microm or 25 microm widths when used with a 211 microm on-center distance. Despite very high radiation doses, the tumors were not sterilized; viable proliferating tumor cells remained present at the tumor margin. This study shows that microbeam width and peak entrance doses strongly influence tumor responses and normal brain toxicity, even if valley doses are kept constant in all groups. The use of 50 microm wide microbeams combined with moderate peak doses resulted in a higher therapeutic ratio.

[1]  Terry M. Button,et al.  RESPONSE OF RAT INTRACRANIAL 9L GLIOSARCOMA TO MICROBEAM RADIATION THERAPY , 2002 .

[2]  Martin Wehling,et al.  Nongenomic actions of steroid hormones , 2003, Nature Reviews Molecular Cell Biology.

[3]  P. Régnard.  Intérêt du rayonnement synchrotron dans la thérapie des tumeurs cérébrales : méthodologie et applications précliniques , 2007 .

[4]  H. Blattmann,et al.  Erratum: “Characterization of a tungsten/gas multislit collimator (TMSC) for microbeam radiation therapy at the European Synchrotron Radiation Facility”[Rev. Sci. Instrum. 76, 064303 (2005)] , 2006 .

[5]  Jennifer A. Smith,et al.  Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy. , 2002, Neuro-oncology.

[6]  M. Di Michiel,et al.  MOSFET dosimetry for microbeam radiation therapy at the European Synchrotron Radiation Facility. , 2003, Medical physics.

[7]  F. Avraham Dilmanian,et al.  Murine EMT-6 Carcinoma: High Therapeutic Efficacy of Microbeam Radiation Therapy , 2003, Radiation research.

[8]  C. Segebarth,et al.  Characterization and quantification of cerebral edema induced by synchrotron x-ray microbeam radiation therapy , 2008, Physics in medicine and biology.

[9]  H. Blattmann,et al.  Characterization of a tungsten/gas multislit collimator for microbeam radiation therapy at the European Synchrotron Radiation Facility , 2005 .

[10]  H. Blattmann,et al.  Dosimetric studies of microbeam radiation therapy (MRT) with Monte Carlo simulations , 2005 .

[11]  I. Troprès,et al.  Irradiation of intracerebral 9L gliosarcoma by a single array of microplanar x-ray beams from a synchrotron: balance between curing and sparing , 2008, Physics in medicine and biology.

[12]  M. Di Michiel,et al.  Physics study of microbeam radiation therapy with PSI-version of Monte Carlo code GEANT as a new computational tool. , 2000, Medical physics.

[13]  Stephen Brown,et al.  Fractionated radiosurgery for 9L gliosarcoma in the rat brain. , 1999, International journal of radiation oncology, biology, physics.

[14]  M. Chopp,et al.  Post-acute response of 9L gliosarcoma to Photofrin™-mediated PDT in athymic nude mice , 2007, Lasers in Medical Science.

[15]  Tomio Inoue,et al.  Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. , 2005, International journal of radiation oncology, biology, physics.

[16]  Alberto Bravin,et al.  First trial of spatial and temporal fractionations of the delivered dose using synchrotron microbeam radiation therapy. , 2009, Journal of synchrotron radiation.

[17]  H. Blattmann,et al.  Prospects for microbeam radiation therapy of brain tumours in children to reduce neurological sequelae , 2007, Developmental medicine and child neurology.

[18]  C. P. Baker,et al.  Histopathologic effect of high-energy-particle microbeams on the visual cortex of the mouse brain. , 1961, Radiation research.

[19]  J. Foidart,et al.  Treating gliomas with glucocorticoids: from bedside to bench , 2006, Acta Neuropathologica.

[20]  A. Bravin,et al.  Effects induced by the fine structure of biological tissues on microbeam dose deposition: A numerical study , 2005 .

[21]  N. Yagi,et al.  A method of dosimetry for synchrotron microbeam radiation therapy using radiochromic films of different sensitivity , 2008, Physics in medicine and biology.

[22]  Marianne Geiser,et al.  Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using a microplanar beam of synchrotron‐wiggler‐generated X rays , 1998, International journal of cancer.

[23]  Jacques Balosso,et al.  Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin , 2007, Journal of Neuro-Oncology.

[24]  D N Slatkin,et al.  Subacute neuropathological effects of microplanar beams of x-rays from a synchrotron wiggler. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Alberto Bravin,et al.  Weanling piglet cerebellum: a surrogate for tolerance to MRT (microbeam radiation therapy) in pediatric neuro-oncology , 2001, Optics + Photonics.

[26]  W Thomlinson,et al.  Research at the European Synchrotron Radiation Facility medical beamline. , 2000, Cellular and molecular biology.

[27]  E. Siegbahn.  Dosimetry for synchrotron x-ray microbeam radiation therapy , 2007 .

[28]  H. Blattmann,et al.  Synergy of gene-mediated immunoprophylaxis and microbeam radiation therapy for advanced intracerebral rat 9L gliosarcomas , 2006, Journal of Neuro-Oncology.

[29]  C. Segebarth,et al.  Brain tumor vessel response to synchrotron microbeam radiation therapy: a short-term in vivo study , 2008, Physics in medicine and biology.

[30]  P. Rubin,et al.  Selective ablation of rat brain tumors by boron neutron capture therapy. , 1994, International journal of radiation oncology, biology, physics.

[31]  P. Randaccio,et al.  The GEANT4 toolkit for microdosimetry calculations: application to microbeam radiation therapy (MRT). , 2007, Medical physics.

[32]  Alberto Bravin,et al.  In vivo two-photon microscopy study of short-term effects of microbeam irradiation on normal mouse brain microvasculature. , 2006, International journal of radiation oncology, biology, physics.

[33]  A. Bravin,et al.  Determination of dosimetrical quantities used in microbeam radiation therapy (MRT) with Monte Carlo simulations. , 2006, Medical physics.